CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 14 enrolled
Drug / intervention
Bariatric surgery +1 moreprocedure
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03294850
NCT03294850N/ACompleted
CompareCT.gov

Evaluation of Biomarkers to Quantify Liver Pathology in Patients With Presumed Non-Alcoholic Steatohepatitis at Baseline and Following Bariatric Surgery (BARI)

AdventHealth Translational Research Institute·interventional·Posted Sep 27, 2017·Updated Jul 16, 2021

In Brief

A clinical study evaluating Bariatric surgery and HepQuant SHUNT Dual Cholate Liver Diagnostic Kit for NASH - Nonalcoholic Steatohepatitis; NAFLD - Nonalcoholic Fatty Liver Disease. Completed, enrolled 14 participants across 1 site.

Detailed Summary

The purpose of this study is to evaluate imaging and other biomarkers of non-alcoholic fatty liver disease before and after bariatric surgery.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsNASH - Nonalcoholic Steatohepatitis; NAFLD - Nonalcoholic Fatty Liver Disease
CountriesUnited States
Collaborators--

Timeline

N/ACompletedFinished
201820192020202120222023202420252026
First PostedSep 27, 2017
Enrollment StartJul 18, 2018
Primary CompletionNov 14, 2019
Study CompletionSep 11, 2020
TodayJul 2, 2026
Enrollment to primary: 1.3 yearsPosted 8.8 years ago

Interventions

Bariatric surgeryprocedure

Subjects enrolling in the study who are undergoing bariatric surgery as part of their medical care will be studied

HepQuant SHUNT Dual Cholate Liver Diagnostic Kitdevice

For the experimental group, the device will be used to monitor the effect of bariatric surgery on liver function. For the active comparator group, the device will be used for the assessment of baseline liver function.